Invention Grant
- Patent Title: Method for treating a GD2 positive cancer
-
Application No.: US14409161Application Date: 2012-07-31
-
Publication No.: US09777068B2Publication Date: 2017-10-03
- Inventor: Hans Loibner , Manfred Schuster , Evelyne Janzek-Hawlat , Susanne Wiederkum , Bernhard Peball , Stefan Stranner , Oliver Mutschlechner , Franz Groiss , Ruth Ladenstein , Holger Lode
- Applicant: Hans Loibner , Manfred Schuster , Evelyne Janzek-Hawlat , Susanne Wiederkum , Bernhard Peball , Stefan Stranner , Oliver Mutschlechner , Franz Groiss , Ruth Ladenstein , Holger Lode
- Applicant Address: AT Vienna
- Assignee: APEIRON BIOLOGICS AG
- Current Assignee: APEIRON BIOLOGICS AG
- Current Assignee Address: AT Vienna
- Agency: Norton Rose Fulbright US LLP
- International Application: PCT/EP2012/064970 WO 20120731
- International Announcement: WO2013/189554 WO 20131227
- Main IPC: C07K16/30
- IPC: C07K16/30 ; A61K39/395 ; A61K31/485 ; A61K45/06 ; A61K39/00
Abstract:
The present invention relates to a method for treating a GD2 positive cancer by administering a preparation comprising an anti-GD2 antibody to a patient as a continuous intravenous infusion over 24 hours per day.
Public/Granted literature
- US20150139942A1 Method for Tretaing a GD2 Positive Cancer Public/Granted day:2015-05-21
Information query
